At the news
? NEUTRALIMPACT 4/10 8-K filed May 6, 2026 at 07:15 ET
TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), slightly better than the $-0.26 EPS in Q1 2025 but a miss vs the $-0.17 consensus estimate. The company reiterated upcoming catalysts including Phase 3 initiation for TSC-101 and early Cohort C data in Q2 2026, while cash burn continues with $128.1M remaining, funding operations into H2 2027.
- Q1 2026 revenue $1.0M vs $2.2M YoY, down 55% due to Amgen collaboration timing
- Net loss $28.7M ($-0.22 EPS) vs $34.1M ($-0.26 EPS) in Q1 2025
- EPS of $-0.22 missed consensus estimate of $-0.17
- Cash and equivalents $128.1M at March 31, 2026, down from $152.4M at year-end 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access